Clinical Trials
11 trialsNCT04129515 2026-01-02
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Brown University
Phase 1/2 Withdrawn
NCT06190249 2025-06-05
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03448666 2024-09-23
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
European Institute of Oncology
Phase 2 Withdrawn
NCT04987996 2023-06-06
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
Phase 2 Withdrawn
NCT04703426 2023-05-22
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04995094 2021-11-05
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
HiberCell, Inc.
Phase 2 Withdrawn
NCT03773744 2021-04-06
Pelican
Turnstone Biologics, Corp.
Phase 1 Withdrawn
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn
NCT02812693 2018-04-05
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Ohio State University Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT02719015 2017-11-24
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02661100 2016-12-07
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn